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Most of the clinically used cytostatic drugs have serious side-
effects. There is much hope that gene therapy will make tumour
therapy more specific, but at present gene therapy is far from being
applicable to larger numbers of patients. Therefore, there is an
urgent and persistent need for new drugs in cancer therapy. Several
attempts have been made to minimize the side-effects of tumour
therapeutics. For example, the urotoxic effects of ifosfamide are
reduced by co-administration of 2-mercapto-ethane-sulphonate
(Mesna) which deactivates acrolein, a metabolite of ifosfamide in
the bladder, but Mesna itself can also lead to unwanted effects
(Shaw and Graham, 1987). In view of the growing importance of
pharmacokinetics in drug design and early clinical trials, new
drugs for cancer chemotherapy should have low molecular weight
to guarantee a clear pharmacokinetic behaviour (Workman, 1997).
The glucose-coupled ifosfamide mustard D19575 (glc-IPM, 
INN = glufosfamide) (Pohl et al, 1995) is a compound which
meets these requirements.
The major toxic effects of ifosfamide are attributed to its
metabolites, especially ifosfamide mustard (IPM) and the urotoxic
acrolein. In glufosfamide, IPM is coupled to C1 of glucose in an
ester-like bond. Because of its glucose moiety the compound is
preferably taken up by cancer cells rather than by normal cells.
Inside the cell it is cleaved by glucosidases, thus liberating the
cytostatic IPM (Seker et al, 1996; Seker, manuscript in prepara-
tion).
Glufosfamide shows a lower myelotoxicity and a higher anti-
tumour activity than ifosfamide, as demonstrated with cultured
cells and with human tumours grown in immunodeficient mice
(Pohl et al, 1995; Stüben et al, 1996; Fiebig, personal communica-
tion). In July 1996, glufosfamide entered a clinical phase I trial
and will enter phase II in 1999. Its mode of action is still under
investigation.
Whereas whole-body autoradiography of the 14C-labelled
compounds did not reveal considerable differences in the distribu-
tion of the b-D- and the b-L-isomers in rats, radioactivity appeared
in brain and tumour only after the administration of b-D-glc-
IPM, strongly suggesting that b-D-glc-IPM is able to cross the
blood–brain barrier (Stüben et al, 1996; Schaper, manuscript in
preparation). Since b-D-glc-IPM is a hydrophilic molecule, it is
assumed that this is due to an active transport mechanism, and it
has been hypothesized that a specific protein is responsible for this
translocation. Recently, it has been reported that a sodium-coupled
transporter (SAAT1 or SGLT3) is indeed responsible for the trans-
port of b-D-glc-IPM into the cell (Veyhl et al, 1998). This is an
example for drug targeting by employing a plasma membrane
transporter.
The aim of the present work was to study the biological conse-
quences of b-D-glc-IPM uptake by cells. Following up a previous
study (Schaper, manuscript in preparation) we measured the effect
of this new cytostatic drug on DNA and protein synthesis as well
as stimulation of PARP activity. Inside the cell, glufosfamide is
split mainly by glucosidases into glucose and ifosfamide mustard,
but also non-enzymatic hydrolysis contributes to its decay. Since
ifosfamide mustard also arises in the metabolism of ifosfamide, we
investigated whether glufosfamide behaves like ifosfamide in the
reaction with DNA. Therefore, we compared the response of cells
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as well as a DNA cross-link repair deficient strain with the corre-
sponding wild-type cells as to b-D-glc-IPM induced cell killing
(Kaina et al, 1991).
MATERIALS AND METHODS
Chemicals
b-D-Glc-IPM was synthesized in the Chemical Research
Laboratories of ASTA Medica AG, Frankfurt, Germany, according
to the method described by Dickes (1988). b-L-Glc-IPM and b-D-
14C-Glc-IPM were synthesized according to a method developed
by Wießler (Veyhl et al, 1998). 14C-label was introduced in the b-
chloroethylamine side chain of the compounds; the specific
radioactivity was 10 mCi mmol–1. The a-/b-anomers were sepa-
rated by recrystallization and column chromatography. Purity of
the substances was > 99%. The absence of isophosphoramide
mustard was ascertained by high-performance liquid chromatog-
raphy (HPLC) and then liquid chromatography (TLC). L-[14C]-
methionine, and [3H-methyl]-thymidine were purchased from
Amersham (Buckinghamshire, UK).
Cells
The generation of strains CHO-9-neo and TK47-AT17-C3 was
described previously (Kaina et al, 1991). CHO-9-neo was derived
from transfection of CHO-9-neo with the neo gene only; it is used
as a MGMT-deficient control. The strain TK47-AT17-C3, which
was transfected with neo plus human MGMT cDNA, expresses
MGMT to a high level (720 fmol mg–1 protein).
The breast carcinoma cell line MCF7 was obtained from the
Tumorbank of the German Cancer Research Center, Heidelberg.
The cells were maintained in RPMI-1640 medium supplemented
with 10% fetal calf serum (Pan Systems, Nürnberg, Germany) and
L-glutamine at 37°C and 5% carbon dioxide in 25 ml flasks until
100% confluency.
The mutant CL-V5B was derived from V79 Chinese hamster
cells (here designated as V79 wild-type (wt)). The line was origi-
nally characterized as mitomycin C hypersensitive and is defective
in DNA cross-link repair (Tellemann et al, 1995). Cells were
kindly provided by Dr M Zdienicka, Leiden, The Netherlands.
They were grown in Dulbecco’s F12 medium containing 10% fetal
calf serum.
Influence of b-D- or b-L-glc-IPM on cell-proliferation
One times 105 MCF7 cells were seeded into Petri dishes (3.5 cm,
4.5 ml medium) and cultivated for 72 h at 37°C. Then, cells were
incubated for 24 h with b-D- or b-L-glc-IPM dissolved in standard
medium (2.5 mM, 5 mM, 10 mM or 25 mM). All assays were carried
out in duplicate. Untreated cells were used as control. After 24 h,
the medium containing b-D-glc-IPM was removed, and cells were
washed with phosphate-buffered saline (PBS) and incubated at
37°C with 2 mCi [3H-methyl]-thymidine for 120 min. Cells were
detached from the culture dishes with 0.25% EDTA, transferred
into 15 ml Falcon tubes and washed three times with PBS, 0.1%
bovine serum albumin (BSA), at 4°C. Cells were precipitated by
the addition of 5 ml trichloroacetic acid (TCA) (10%) and left on
ice for 20 min. Precipitates were collected by centrifugation at 
770 g, 4°C for 10 min and solubilized with 200 ml of formic acid.
Radioactivity was measured in a Tricarb Liquid Scintillation
Analyzer (Packard Instruments Groningen, The Netherlands).
Influence of b-D- or b-L-glc-IPM on protein synthesis
One times 105 MCF7 cells were seeded into Petri dishes (4.5 mL
medium) and cultivated for 120 h at 37°C. Further steps were the
same as described above for the proliferation assay. L-[methyl
14C]-methionine (2 mCi ml–1) was used as radiolabelled compound.
All assays were carried out in duplicate. Untreated cells were used
as control.
Influence of b-D- or b-L-glc-IPM on induction of PARP
activity
For the detection of poly(ADP)-ribose synthesized in MCF7 cells
as a consequence of b-D- or b-L-glc-IPM treatment, cells grown on
cover-slips (60% confluence) were incubated with different
concentrations of glc-IPM for different time intervals. Thereafter
cells were washed with PBS and fixed with 10% ice-cold TCA.
Poly(ADP-ribose)-specific immunofluorescence was performed
as described (Bürkle et al, 1993). Cells treated with g-rays (10 min
at 8.4 Gy min–1) were used as positive controls.
Influence of b-D- or b-L-glc-IPM on cytotoxicity in repair-
deficient strains
Cells were routinely grown in Dulbecco’s modified Eagle’s
medium (DMEM) F12 medium (1:1) supplemented with 5% of
inactivated fetal calf serum and G418 (1.5 mg/ml). G418 was
omitted during the experiments. For determination of survival of
CL-V5B and V79 wt cells as well as CHO-9 and TK47-AT17-C3
cells upon treatment with glufosfamide, colony formation was
assayed. Cells were seeded (500–6000 cells per 5-cm dish) and
treated 6 h later by adding appropriate amounts of the stock solu-
tion to the culture medium. If not stated otherwise, cells were
exposed to glufosfamide for 60 min. Thereafter they were rinsed
once with medium and fresh medium was added. After 6–8 days,
plates were rinsed with PBS and colonies were fixed with
methanol and stained with Giemsa-crystal-violet. Relative cell
survival was expressed as colonies per treatment level/colonies on
the control plates. Data are means of at least three independent
experiments.
RESULTS
In previous experiments, genotoxic activity of b-D-glc-IPM was
shown by using the comet assay (Schaper et al, manuscript in
preparation). Here we continued this study by investigating the
effects of glufosfamide on proliferation and on cellular DNA
monitored by the DNA strand-break-dependent formation of
poly(ADP-ribose). Furthermore we studied b-D-glc-IPM cytotox-
icity in repair-deficient cells in order to investigate the relevance
of possible O6-alkylating or cross-linking effects of glufosfamide.
Figure 1A shows that b-D-glc-IPM induced a concentration-
dependent decrease in proliferation as measured by the incorpora-
tion of [3H-methyl]-thymidine into DNA of MCF7 cells. Starting
with a 10% decrease after addition of 2.5 mM b-D-glc-IPM to the
cells, the inhibition of DNA synthesis was 50% at 25 mM. The
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inhibition of DNA synthesis only at the highest concentration (25
mM) of this isomer.
Figure 1B shows that 10 mM and 25 mM b-D-glc-IPM lowered
the protein synthesis in MCF7 cells, measured by 14C-methionine
incorporation into protein of these cells by 50% and about 70%,
respectively. The influence of b-L-glc-IPM was again less
pronounced, showing a 25% inhibition of protein synthesis only at
a concentration of 25 mM.
Poly(ADP-ribosyl)ation is a post-translational modification of
nuclear proteins which is triggered by DNA strand-breaks and
therefore can serve as a marker for genotoxic effects (Figure 2
A–H). The method developed by Bürkle et al (1993) is based on
the fact that DNA strand-breaks, as induced directly by ionizing
radiation or arising in the course of DNA base excision repair,
induce activation of poly(ADP-ribose) polymerase. The treatment
of MCF7 cells with g-rays and subsequent immunofluorescence
assay of poly(ADP-ribose) formation induced fluorescence signals
in a dose-dependent manner, proving the reliability of this test
system in MCF7 cells and the inducibility of poly(ADP-
ribosyl)ation. Figure 2 h shows the effect of a 10-min irradiation
with 8.4 Gy min–1. The effects of an incubation of MCF7 cells with
50 mM, 250 mM and 750 mM glufosfamide for 24 h are shown in
Figure 2 B,C,D. It is evident that PARP activity was triggered by
b-D-glc-IPM at concentrations as low as 50 mM. The b-L-isomer
led also to an induction of PARP-activity but only at a concentra-
tion of 750 mM (Figure 2F).
Survival of MGMT-deficient and MGMT-proficient CHO cells
(strains CHO-9-neo and Tk47-AT17-C3 respectively) upon treat-
ment with glufosfamide is shown in Figure 3A. There was no
difference in survival between both strains indicating that O6-
alkylguanine, which is subject to repair by MGMT, is not formed
at significant amounts after treatment with the drug, or alterna-
tively, that this lesion does not persist long enough, perhaps due to
the rapid conversion of the monoadduct into a DNA cross-link. On
the other hand, the cross-link repair-deficient cell line CL-V5B
was clearly hypersensitive to glufosfamide as compared to V79
wt, which is indicative of cross-link formation by the agent. It
should be noted that CHO-9 cells were more resistant than V79 wt.
The reason for this strain difference is unknown, but it is tempting
to speculate that either cross-link repair is more efficient, or the
uptake by glucose transporter occurs less efficiently in CHO than
in V79 cells. A further explanation could be that the content of b-
glucosidases in CHO cells necessary for metabolic activation of
glufosfamide is possibly lower than that of V79 cells.
DISCUSSION
The molecular basis for the neoplastic behaviour of advanced
tumours is largely undefined (Monks et al, 1997). Notably, the
target for drug intervention is unclear. Here we concentrated on
effects of the cytostatic compound glufosfamide on DNA in MCF7
cells concerning proliferation and repair. Toxic effects of glufos-
famide on DNA and on protein synthesis in MCF7 cells, indicative
of a genotoxic activity of this compound, were observed already at
low doses. The effects on DNA became apparent between 2 and 
5 mM, shown by an impaired incorporation of [3H-methyl]-thymi-
dine into DNA of these cells. The L-isomer exerted similar effects
but at higher concentrations. We suppose that this effect is due to
partial hydrolysis of b-L-glc-IPM liberating the IPM-moiety,
because cells were incubated for 24 h after which time hydrolysis
has already begun. The inhibition of DNA and protein syntheses is
probably due to alkylating properties of glufosfamide. IPM, which
arises in the metabolism of glufosfamide, is a powerful alkylating
agent (Hemminki, 1986) and may react with cellular components
involved in protein synthesis like ribosomes, ribosomal RNA or
proteins involved in translation processes (Monks et al, 1997), thus
leading to an impairment thereof.
One of the first responses of eukaryotic cells to some types of
DNA damage is the covalent modification of nuclear proteins with
poly(ADP-ribose). Poly(ADP-ribosyl)ation is catalysed by the
nuclear enzyme poly(ADP-ribose) polymerase (PARP; EC
2.4.2.30) which utilizes NAD+ as substrate (for review see:
DeMurcia and Ménissier-de Murcia, 1994; Lindahl et al, 1995;
Oci et al, 1997). The two zinc fingers in the aminoterminal DNA-
binding domain of PARP mediate the recognition of single- or
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Figure 1 Effects of various concentrations of b-D-glc-IPM and b-L-glc-IPM on DNA (A) and protein (B) biosynthesis in MCF7 cells. Radioactivity (DPM)
measured in the control cultures has been set as 100%632 H Seker et al
British Journal of Cancer (2000) 82(3), 629–634 © 2000 Cancer Research Campaign
b -D-Glucose-IPM
750mM
500mM
b -L-Glucose-IPM
50mM
750mM
500mM
pos. Control
(10 min radiation at 8.4 Gy min
–1)
neg.control
A
B
C
D
E
F
G
H
Figure 2 Immunodetection of poly(ADP-ribose) induced by various concentrations of b-D-glc-IPM in MCF7 cells. Cells were treated for 24 h. b-L-Glc-IPM which
has no cytostatic activity has been used as control substance. (A) b-D-glc-IPM 0 mM; (B), 750 mM; (C), 500 mM; (D), 50 mM; (E), b-L-glc-IPM 0 mM; (F), 750 mM; 
(G), 500 mM; (H), positive control (10 min at 8.4 Gy min–1)double-strand-breaks in DNA, thus triggering the activation of the
catalytic centre in the carboxyterminal NAD+-binding domain. As
a consequence, exposure of cells to certain chemical or physical
DNA-damaging agents (including reactive oxygen species, alkyl-
ating agents, and g-radiation) induces a dose-dependent stimula-
tion of cellular poly(ADP-ribose) synthesis.
While the biological functions of PARP have not yet been fully
eludicated at the molecular level, cellular poly(ADP-ribose)
formation may be used as a marker for the infliction of at least
some types of DNA damage, and this can be conveniently assessed
in situ by immunofluorescence (Bürkle et al, 1993), using a mono-
clonal antibody directed against poly(ADP-ribose) (Kawamitsu et
al, 1984). Together with previous results on genotoxic effects of
glufosfamide as revealed by the comet assay (Schaper et al, manu-
script in preparation), the data presented here strongly suggest
DNA alkylating properties of glufosfamide. However, in the
comet assay the concentration needed to induce detectable DNA
damage was very high (10 mM). By contrast, in the present work
we could demonstrate that PARP activity, as detected by an
immunofluorescence assay (Bürkle et al, 1993), was induced
already at a much lower concentration of glufosfamide (50 mM).
The question of whether this DNA-damage was mainly due to O6-
alkylation processes or to cross-links produced by glufosfamide
was addressed by using repair-deficient cell strains. It became
apparent that cross-linking was much more toxic than O6-alkyla-
tion. The concentrations of glufosfamide needed to produce DNA
damage either in the PARP or in the cross-linking assay were in the
mM range. In contrast, in the comet assay the appropriate concen-
trations were in the mM range. We suppose that this discrepancy is
a result of the strong cross-linking effects of the metabolite ifos-
famide mustard, preventing the DNA-pieces from forming the
characteristic comet at concentrations which show activation of
PARP. Similar results regarding cross-linking agents investigated
in the comet assay have been described (Pfuhler and Wolf, 1996).
Experiments are underway to investigate whether suppression of
PARP by appropriate inhibitors may increase the therapeutic
potency of glufosfamide. The L-isomer led also to an activation of
repair mechanisms but the concentrations needed were more than
ten times higher than with the b-D-isomer. The reason is again seen
in the formation of IPM which is hydrolytically formed after 24 h
of incubation. Results from our comparison of repair-deficient and
-proficient strains showed that glufosfamide obviously did not
induce DNA O6-alkylation which can be repaired by MGMT, but
led to cross-link formation. Together with other results reported
here, this shows a certain similarity of glufosfamide to ifosfamide
suggesting that its cytotoxic effects are mainly due to IPM, the
metabolite of both compounds. Yet the toxicity of glufosfamide in
white blood cells, colony forming units and spleen colony forming
units is considerably lower as compared to ifosfamide (4). Another
exciting difference between ifosfamide and glufosfamide was
demonstrated by Volm and colleagues who were able to provoke
resistance of cells upon continuous drug treatment against ifos-
famide but not against glufosfamide in SKOV3 cells (Volm,
personal communication).
A necessary requirement for the therapeutic efficacy of saccha-
ride-conjugates is their activation in the target cells. We suppose
that the conjugates have to be split by glucosidases to liberate the
therapeutic moiety. In a forthcoming paper we will report on the
correlation between the content of b-glucosidases in different cell
lines and their sensitivity against glufosfamide.
In conclusion, we have shown that the cytostatic compound
glufosfamide impaired protein and DNA synthesis in MCF7 cells
and that it triggered the activation of PARP, an enzyme specifically
sensing DNA strand-breaks, at concentrations of 5 mM and 50 mM
respectively. The major cytotoxic lesions are probably due to
cross-linking effects rather than monofunctional alkylations
exerted by glufosfamide, as shown by comparison of isogenic cell-
lines deficient and proficient of cross-link repair. In view of the
minute amounts of glufosfamide taken up by the cells (Schaper et
al, manuscript in preparation), it is surprising that very low
concentrations of the drug can lead to the observed striking effects
at the DNA level. Further investigations on this issue are in
progress.
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